A clinical follow-up (every 3–6 months for the first 2 years, then annually): comprehensive physical examination and blood tests, including complete blood count (CBC), lactate dehydrogenase (LDH) as a marker of lymphoma activity, tumor markers (CEA, CA 15-3), and liver and renal function tests. The gene discussed is CEACAM5; the disease is neoplasm.